Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
16. |
ECCT/24/03/07 | Gates MRI TBV02-301 A Phase 3, randomized, double-blind, placebo-controlled, multicenter, clinical trial to assess the prophylactic efficacy, safety, and immunogenicity of the investigational M72/AS01E-4 Mycobacterium tuberculosis (Mtb) vaccine when administered intramuscularly on a 0,1-month schedule to adolescents and adults. |
Principal Investigator(s) 1. Prof Walter Godfrey Jaoko Site(s) in Kenya 1. KAVI – Institute of Clinical Research (KAVI - ICR) (Nairobi City county) |
View |
17. |
ECCT/24/04/01 | B/F/TAF to DTG/3TC Switch Stud Efficacy, Safety and Tolerability of Switching to DTG/3TC Single Tablet Regimen from B/F/TAF in Older Persons Living with HIV in Kenya |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county) 2. Kenyatta National Hospital (Nairobi City county) |
View |
18. |
ECCT/24/03/06 | PHOENIx MDR-TB) Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB) |
Principal Investigator(s) 1. Dr Lucy Chepkurui Koech KOECH Site(s) in Kenya 1. Kenya medical Research Institute/ Walter Reed Project (Kericho county) 2. Moi university clinic research Centre (Uasin Gishu county) |
View |
19. |
ECCT/24/03/04 | MK8591A-053 Trial A Phase 3, Randomized, Active-Controlled, Double-Blind Clinical Study to Evaluate the Antiretroviral Activity, Safety, and Tolerability of Doravirine/Islatravir (DOR/ISL 100 mg/0.25 mg) Once-Daily in HIV-1 Infected Treatment-Naïve Participants |
Principal Investigator(s) 1. Elizabeth Anne Bukusi 2. Nelly Rwamba Mugo Site(s) in Kenya 1. Site 8650, KEMRI-CMR-RCTP, Kisumu (Kisumu county) 2. Site 8651, KEMRI-CCR-PHRD, Thika (Kiambu county) 3. Site 8652, KEMRI-CCR, NAIROBI (Nairobi City county) |
View |
20. |
ECCT/24/03/02 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a Respiratory Syncytial Virus vaccine in infants and toddlers (PEARL |
Principal Investigator(s) 1. Dr. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI CCR – Butere Clinical Research Centre (Kakamega county) |
View |